List of Excipients in Branded Drug CUPRIMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	CUPRIMINE	penicillamine	25010-705	D&C YELLOW NO. 10
Bausch Health US LLC	CUPRIMINE	penicillamine	25010-705	GELATIN
Bausch Health US LLC	CUPRIMINE	penicillamine	25010-705	LACTOSE MONOHYDRATE
Bausch Health US LLC	CUPRIMINE	penicillamine	25010-705	MAGNESIUM STEARATE
Bausch Health US LLC	CUPRIMINE	penicillamine	25010-705	TITANIUM DIOXIDE

Cuprimine Excipient Strategy and Commercial Opportunities for Penicillamine

Last updated: August 10, 2026

Cuprimine is an oral D-penicillamine product used for Wilson disease, cystinuria, and selected refractory rheumatoid arthritis cases. Its commercial value is driven less by novel active-ingredient IP and more by supply reliability, excipient control, bioequivalence, tolerability, and regulatory execution. The strongest opportunities are generic or authorized-generic supply, differentiated low-excipient formulations, capsule-shell alternatives, and manufacturing platforms that reduce variability in a narrow-market product.

What is Cuprimine and which excipients does it contain?

Cuprimine contains penicillamine, a thiol-containing chelating agent. The product is supplied as oral capsules in 125 mg and 250 mg strengths. FDA labeling identifies inactive ingredients that include lactose, magnesium stearate, starch, and capsule-shell components such as gelatin and colorants, although the precise composition should be confirmed against the current product label and approved application. [1]

Product attribute	Cuprimine profile
Active ingredient	D-penicillamine
Dosage form	Immediate-release oral capsule
Strengths	125 mg and 250 mg
Main indications	Wilson disease, cystinuria, refractory rheumatoid arthritis
Administration	Oral; generally administered on an empty stomach
Key formulation issue	Low-dose, narrow-market product with significant tolerability and adherence requirements
Primary excipient considerations	Lactose, starch, magnesium stearate, gelatin, colorants
Regulatory pathway for competitors	Abbreviated New Drug Application, subject to FDA requirements
Primary commercial differentiator	Reliable supply, formulation equivalence, patient tolerability, and access

D-penicillamine is chemically reactive because of its sulfhydryl group. The formulation must control exposure to moisture, oxygen, heat, and trace metals. Manufacturing controls, container closure, and excipient quality can have greater commercial importance than the nominal cost of individual excipients.

What excipient strategy is appropriate for a penicillamine capsule?

The most defensible strategy is a conservative immediate-release capsule that minimizes excipient changes while improving manufacturability and patient acceptability.

Maintain a simple, compendial excipient system

A conventional formulation can use a diluent, disintegrant or filler, lubricant, and hard gelatin capsule shell. Suitable excipient classes may include:

• Lactose monohydrate or an alternative carbohydrate diluent
• Pregelatinized starch or maize starch
• Crospovidone or sodium starch glycolate where disintegration requires optimization
• Magnesium stearate or another qualified lubricant
• Gelatin or hypromellose capsule shells
• Titanium dioxide or approved colorants, subject to jurisdictional requirements

A formulation should avoid unnecessary excipient complexity. Each additional excipient increases the scope of extractables, elemental impurities, compatibility testing, supplier qualification, and post-approval change management.

Assess lactose as both a cost and market-access variable

Lactose is inexpensive and widely used, but it can create commercial limitations for patients with lactose intolerance or for purchasers seeking lactose-free products. Lactose content in a capsule is generally small, but a lactose-free claim may have value in specialty pharmacy channels and among patients who attribute gastrointestinal symptoms to excipients.

A lactose-free version could use microcrystalline cellulose, mannitol, starch, or a suitable combination. The substitution would require comparative dissolution, stability, content uniformity, impurity, and bioequivalence work. A lactose-free formulation is unlikely to support broad premium pricing by itself, but it may strengthen differentiation in a product with limited competition.

Evaluate gelatin-free capsule shells

A hypromellose capsule could target vegetarian, religious, and certain institutional procurement requirements. The principal development risks are capsule-machine performance, moisture transfer, shell brittleness, fill-weight variation, and stability under the product's storage conditions.

A gelatin-free product is commercially more credible as a secondary SKU than as the first generic launch. The lead product should normally use the lowest-risk shell material that is consistent with the reference product and bioequivalence requirements.

Control lubrication and blend uniformity

Magnesium stearate can affect powder wetting and dissolution when over-lubrication occurs. This risk matters in a low-dose product because the formulation may require a relatively large excipient fraction to achieve target fill weight. Process controls should cover blending time, lubricant addition, segregation, capsule fill variation, and dissolution after scale-up.

The most important manufacturing objective is not maximum dissolution rate. It is reproducible release that matches the reference product across the proposed strength range.

What excipients may create regulatory or patient-safety barriers?

The main risks are incompatibility, intolerance, labeling complexity, and product-quality variability.

Lactose intolerance

Lactose can limit use in patients with documented intolerance. Wilson disease patients may remain on therapy for years, making cumulative tolerability and adherence commercially relevant. A lactose-free option can support switching without changing the active ingredient or dosing schedule.

Colorants

Colorants add little therapeutic value and can complicate procurement in markets that restrict specific dyes. A color-free capsule can reduce the number of formulation components and may improve acceptance among patients and caregivers. The tradeoff is lower visual differentiation and potentially less protection against medication mix-ups.

Gelatin

Gelatin creates animal-origin and dietary issues. A hypromellose shell can broaden market access, but the change must be supported by stability and performance data. Shell material also affects moisture exchange, which is relevant to a chemically reactive active ingredient.

Trace metals and peroxide impurities

Penicillamine's thiol chemistry makes control of trace metals and oxidative impurities important. Excipient suppliers should provide suitable specifications for elemental impurities, peroxides, residual solvents, and microbial quality. The drug product manufacturer should establish a risk-based control strategy under ICH Q3D and ICH Q9 principles. [2,3]

Excipient variability

Large changes in particle size, moisture content, bulk density, or surface area can affect fill weight, blend uniformity, and dissolution. A low-volume product may be exposed to greater supply-chain risk because it has fewer qualified suppliers and lower purchasing leverage.

What formulation patents protect Cuprimine?

Cuprimine is an established small-molecule product, and its commercial protection is not generally based on a recent composition-of-matter patent. Public FDA product information identifies the product as an oral penicillamine capsule rather than a platform protected by a modern delivery-system patent. [1,4]

The relevant IP questions for a competing product are usually:

1. Whether any active Orange Book-listed patents remain associated with the reference product.
2. Whether a competitor is relying on a formulation, process, or method-of-use patent outside the Orange Book.
3. Whether a proposed product copies a protected capsule composition or manufacturing process.
4. Whether any patent claims cover a specific excipient combination, stability system, or delivery technology.

For an immediate-release penicillamine generic, a new patent estate would likely need to focus on a technically meaningful distinction, such as:

• Improved stability against oxidation
• A low-metal or low-peroxide excipient system
• A lactose-free formulation with equivalent exposure
• A gelatin-free capsule with improved moisture protection
• A modified release profile, if clinically justified
• A manufacturing process that reduces degradation or content variability

A patent directed only to routine substitutions of lactose, starch, or magnesium stearate would face patentability and commercial-value challenges unless supported by unexpected technical results.

When does Cuprimine lose exclusivity and what is the generic-entry risk?

Cuprimine's core small-molecule exclusivity is mature. The commercial barrier is therefore regulatory execution and supply economics rather than statutory exclusivity.

Exclusivity factor	Commercial assessment
New chemical entity exclusivity	Expired for this established active ingredient
Core composition-of-matter protection	Not a current practical barrier to ordinary generic development
Formulation patent risk	Potentially relevant only if a live, enforceable claim covers the proposed product
Method-of-use patent risk	More relevant to specific indications than to ordinary product supply
Orphan exclusivity	Wilson disease may have orphan-drug regulatory history, but product-level orphan exclusivity must be assessed separately from the active ingredient's age
Generic pathway	ANDA with bioequivalence and chemistry, manufacturing, and controls data
Launch risk	Moderate to high because of small market size, limited suppliers, and possible supply interruptions

A generic applicant would need to address patent certifications in its ANDA. If relevant listed patents exist, the applicant could use a Paragraph III or Paragraph IV certification depending on the patent and commercial strategy. A Paragraph IV filing could trigger patent litigation under the Hatch-Waxman framework, but the expected litigation burden appears lower than for heavily patented branded products. [4,5]

What is the Orange Book status of Cuprimine?

The FDA Orange Book is the controlling source for current listed patents, exclusivity, therapeutic-equivalence codes, and reference-listed-drug information. [4] Cuprimine's commercial analysis should distinguish among:

• The brand product's current marketing status
• The reference-listed-drug designation
• Any listed patents
• Approved generic applicants
• Therapeutic-equivalence ratings
• Any discontinued or withdrawn presentations

A product can remain commercially important even when its patent protection is weak if few manufacturers are willing to support the application. This is common in low-volume products with complex supply requirements and limited reimbursement upside.

What generic launch scenarios exist for penicillamine?

Scenario 1: Standard bioequivalent generic

This is the lowest-cost entry model. The applicant matches the reference product's strength, capsule format, release profile, and excipient architecture as closely as permitted. The main advantage is a shorter development path and lower physician-switching friction.

The disadvantage is limited differentiation. Price competition can compress margins quickly if multiple suppliers enter.

Scenario 2: Authorized generic or licensed supply

An authorized generic can use the brand owner's formulation or manufacturing network while competing on price. This model can reduce development risk and improve continuity of supply. It is attractive where the brand owner wants to retain channel access without maintaining a separate premium brand position.

Scenario 3: Lactose-free or excipient-reduced product

This product could target patients with excipient intolerance and specialty pharmacies. The commercial opportunity depends on whether payers and prescribers recognize the formulation difference. The product should avoid unsupported superiority claims.

Scenario 4: Dual-source hospital and government supply

A manufacturer can compete through supply contracts based on reliability, lead time, and shortage resilience. The value proposition would include validated alternate excipient suppliers, redundant packaging capacity, and conservative inventory levels.

Scenario 5: Reformulated product with a 505(b)(2) strategy

A reformulation with a meaningful clinical or pharmacokinetic difference could potentially use a 505(b)(2) pathway, depending on the product design and regulatory basis. [6] Examples might include a new dosage form, modified release, or clinically relevant tolerability improvement. This strategy carries materially higher development and regulatory costs than an ANDA.

Which companies are challenging or competing with Cuprimine?

Competition is likely to come from generic penicillamine manufacturers rather than from a large branded pipeline. The relevant competitor set includes:

• Approved manufacturers of penicillamine capsules
• Potential ANDA applicants
• Compounding pharmacies, where permitted
• Alternative chelators used in Wilson disease
• Alternative cystinuria therapies
• Other disease-modifying treatments for rheumatoid arthritis

The principal therapeutic alternatives are not direct formulation substitutes. Trientine and zinc products are important Wilson disease comparators, while urinary alkalinization, hydration, and other interventions may be used in cystinuria. The competitive threat depends on indication, treatment stage, physician preference, tolerability, and availability rather than on molecule-to-molecule substitution alone.

How strong is the Cuprimine patent estate?

The patent estate is strategically weak compared with newer specialty drugs because penicillamine is an old active ingredient and the product uses a conventional oral dosage form. The stronger barriers are operational:

Barrier	Relative impact
Core compound patent	Low
Conventional capsule formulation patent	Low
Bioequivalence and CMC execution	Moderate
Stability and impurity control	Moderate to high
Supplier concentration	High
Small market size	High
Physician and patient switching friction	Moderate
Reimbursement leverage	Moderate
Shortage-related supply value	High

A competitor should treat manufacturing know-how and supply continuity as the principal defensible assets. Process patents may have value if they demonstrate a measurable reduction in oxidation, degradation products, or batch failures. Trade secrets covering raw-material controls, blending, encapsulation, and packaging may be more useful than narrow formulation claims.

What commercial opportunities exist in Cuprimine excipients?

The most credible opportunities are:

1. A lactose-free capsule for long-term users with excipient intolerance.
2. A gelatin-free capsule for institutional and international procurement.
3. A color-free formulation with a simpler label and fewer sourcing constraints.
4. A formulation supported by stronger oxidative and elemental-impurity controls.
5. A dual-source excipient and packaging platform designed to prevent shortages.
6. An authorized-generic or contract-manufacturing arrangement.
7. A specialty-pharmacy product with patient-support services focused on adherence and laboratory monitoring.
8. Regional manufacturing aligned with government procurement and shortage-prevention programs.

Revenue potential is constrained by the narrow patient population and established generic competition. The opportunity is better suited to a focused specialty-generic company than to a large pharmaceutical company requiring blockbuster-scale returns.

What patent litigation affects Cuprimine?

Cuprimine is not generally associated with the high-volume patent litigation profile seen in oncology, diabetes, immunology, or biologic products. The key litigation checks are current Orange Book listings, ANDA Paragraph IV notices, district-court filings under 35 U.S.C. §271(e)(2), and any settlement agreements involving generic launch dates. [4,5]

The absence of major litigation does not eliminate launch risk. A manufacturer can face commercial loss from a failed bioequivalence study, a stability deficiency, a supplier disruption, or a product recall without any patent case.

Key Takeaways

• Cuprimine is an established oral penicillamine capsule with limited practical patent-based protection.
• The formulation opportunity is centered on excipient simplification, lactose elimination, capsule-shell choice, and oxidative-stability control.
• A standard ANDA is the most efficient entry route for a conventional generic.
• A lactose-free or gelatin-free formulation can create differentiation but requires comparative quality and bioequivalence support.
• Manufacturing reliability is a stronger commercial barrier than composition-of-matter IP.
• Supply contracts, authorized-generic arrangements, and shortage-resilient sourcing may produce more value than premium branding.
• Any current patent, exclusivity, or Paragraph IV conclusion must be verified against the FDA Orange Book and current court records before a filing or transaction.

FAQs

Is Cuprimine lactose-free?

The labeled Cuprimine formulation has historically included lactose or a lactose-containing excipient system. Product-specific labeling should be checked before prescribing or substituting.

Can penicillamine be formulated in a hypromellose capsule?

Yes. A hypromellose shell is technically feasible, but the applicant must demonstrate acceptable stability, capsule performance, dissolution, and bioequivalence.

Does Cuprimine require a special container closure?

A moisture- and oxygen-controlled package is commercially prudent because penicillamine contains a reactive sulfhydryl group. The final package should be established through stability studies.

Is a lactose-free penicillamine product patentable?

Possibly, but a simple lactose substitution may not be sufficient. Patentability would depend on claim scope, prior art, and evidence of unexpected technical or clinical results.

Is penicillamine a biologic with biosimilar risk?

No. Penicillamine is a synthetic small-molecule drug. Competitors generally pursue generic-drug pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (n.d.). Cuprimine (penicillamine) capsules prescribing information. DailyMed.
2. International Council for Harmonisation. (2023). ICH Q3D(R2): Guideline for elemental impurities.
3. International Council for Harmonisation. (2023). ICH Q9(R1): Quality risk management.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. §355 and 35 U.S.C. §271(e).
6. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).